Install
Stay informed on the latest biopharmaceutical news, trends, and developments in Asia Pacific with BioPharma APAC. BioPharma Asia ( APAC ) provides in-depth analysis, insights, and expert commentary on drug development, regulatory updates, and industry partnerships in the region.
- 60articles · 30d
- 14+ hour agolatest article
- Aug 15, 2026earliest in window
- 97%with images
- 212avg words
- Medical 45
- Health & Wellness 36
- Economy, Business & Finance 23
- Health 20
- Business & Industrial 19
- Science & Technology 17
- Science & Nature 7
- Finance & Business 6
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
US FDA Grants Fast Track Designation to T-MAXIMUM’s Allogeneic CAR-T Therapy for Recurrent Glioblastoma
1+ week, 5+ day ago (247+ words) 02 September 2026 | Wednesday | News T-MAXIMUM PHARMACEUTICAL Inc. ("T-MAXIMUM") announced that its investigational allogeneic CAR-T cell therapy MT027 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma. MT027 had previously received FDA Orphan…...
Convergen Raises $15M Seed+ to Accelerate Targeted Protein Degradation Therapies
1+ week, 5+ day ago (60+ words) 02 September 2026 | Wednesday | News The proceeds will be used to further advance Convergen's proprietary degrader platform and accelerate its pipeline for neurodegenerative disorders and other protein aggregation diseases. Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence China Plus…...
HaemaLogiX Doses First Patient with KMCAR T-Cell Therapy in Phase 1 Multiple Myeloma Trial
1+ week, 6+ day ago (207+ words) 27 August 2026 | Thursday | News HaemaLogiX Ltd is pleased to announce another milestone in its ongoing Phase 1 KOALA trial, with the first patient having been safely treated with KMCAR™ T-cell therapy. Following an initial infusion, the patient demonstrated that the treatment was…...
Data4Life, Monash Health Partner to Accelerate Clinical Trials and Real-World Evidence Generation
1+ week, 6+ day ago (180+ words) 01 September 2026 | Tuesday | News Data4Life and Monash Health have partnered to optimize clinical trial design and execution, complemented by educational workshops and professional training programs, with a shared commitment to improving patient outcomes. The Global Relations Office is a new site launched…...
DualityBio, Genentech Ink $1B-Plus Deal to Develop Next-Generation ADCs Against Drug-Resistant Tumours
2+ week, 15+ hour ago (234+ words) 31 August 2026 | Monday | News DUALITYBIO Inc. announced that it has entered into a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates ("ADCs") built on the Company's proprietary DualityBio Unique Payload Antibody Conjugate…...
Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours
3+ week, 3+ hour ago (742+ words) BioPharma APAC - Taiwan’s Anbogen Partners University of Tokyo to Advance ABT-301 Across Solid Tumours 24 August 2026 | Monday | News Anbogen Therapeutics Inc. (TPEx: 7784) ("Anbogen" or the "Company"), a clinical-stage precision oncology company, announced that it has entered into a Collaborative Research Agreement…...
Akeso Secures China Clinical Trial Clearance for B7-H3 ADC AK157D1
3+ week, 8+ hour ago (172+ words) 24 August 2026 | Monday | News AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline. B7-H3 is highly expressed in a broad…...
US FDA Grants Breakthrough Therapy and Fast Track Designations to NORROY’s 68Ga-NYM096 for Kidney Cancer Imaging
3+ week, 3+ day ago (142+ words) 21 August 2026 | Friday | News 68Ga-NYM096 is the first China-originated innovative radiopharmaceutical to receive FDA Breakthrough Therapy Designation. It is being developed as a non-invasive PET imaging agent to enable the characterization of indeterminate renal masses identified by Computed Tomography (CT) or Magnetic…...
Pillar Biosciences, LC-SCRUM-Asia and LSI Medience Partner on Large-Scale Lung Cancer Genomic Screening in Japan
3+ week, 3+ day ago (265+ words) 21 August 2026 | Friday | News Pillar Biosciences, Inc. ("Pillar"), LC-SCRUM-Asia and LSI Medience Corporation ("LSI Medience") announced a collaboration to support genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan. Following approval of…...
AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma
3+ week, 6+ day ago (58+ words) 18 August 2026 | Tuesday | News The registrational Phase II clinical trial of C-CAR039 for r/r LBCL in CAR-T therapy naïve patients in China is still ongoing. Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence China Plus One: Slogan, Strategy,…...